Zai Lab reports FY2021 results; financial details not provided in 8-K exhibit

Zai Lab Ltd

2022-FY EPS reported -$0.76 revenue$144,312,000

Announced financial results for FY2021; specific revenue and EPS figures not provided in the filing.
Forecasts peak-year sales from lung and GI cancer franchises could reach $2.5–3B by 2030.
Proposed share subdivision of ordinary shares (1:10) to increase liquidity on HKEX; shareholder vote sought.
Plans to submit NDA for efgartigimod in gMG in China in mid-2022; multiple clinical milestones.
Entered license agreements for KarXT (neuroscience) and BLU-945/701 (EGFR NSCLC) in Greater China.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.